Findings show persistent posttreatment genital hypoesthesia among sexual and gender minority youth with history of antidepressant use
SSRI-exposed children did not have increased risk of functional nausea and vomiting or functional abdominal pain disorders
Warnings for youth resulted in marked increases in psychotropic drug poisonings and suicide deaths
Proportion of telehealth prescriptions climbed across medications
Only high-dose psilocybin was better than placebo in antidepressant trials of escitalopram
Patients treated with antidepressants whose symptoms do not improve show more relapses in alcohol use disorder
CYP2D6-inhibiting antidepressants linked to worse outcomes than CYP2D6-neutral antidepressants when used with CYP2D6-metabolizing opioids
Higher risk seen for gaining weight with escitalopram, paroxetine, duloxetine; lower risk with bupropion
Higher frequencies of discontinuation symptoms seen in association with desvenlafaxine, venlafaxine, imipramine, and escitalopram
Bipolar diagnosis substantially cuts inpatient care in all age groups, which coincided with drop in antidepressant use